|  |
| --- |
| IRB Member Reviewer Name: Click or tap here to enter text. |
| [ ]  **I confirm that I do not have any conflicts of interest with this study or study team.** |
| Protocol Title: Click or tap here to enter text. |
| **PI** | **Project Number** | **Date** |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap to enter a date. |
| **Exempt Category:** [ ]  **2(iii)** [ ]  **3(i)(c)** [ ]  **7** [ ]  **8(iii)***For categories 7 and 8 - the broad consent document used in this study must be included with the application for review.* |
| **Review Criteria for Categories 2(iii), 3(i)(c), 7 and 8(iii) under** [**45CFR46.104(d)**](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/revised-common-rule-regulatory-text/index.html#46.104) |
| **Privacy and Confidentiality** |
| [ ]  **YES** [ ]  **NO** | Are there adequate provisions to protect the privacy of subjects? |
| [ ]  **YES** [ ]  **NO** | Are there adequate provisions to protect the confidentiality of data? |
| **Additional Review Criteria for Categories 7 and 8 (not applicable to 2(iii) or 3(i)(c))** |
| [ ]  **YES** [ ]  **NO** | Is the broad consent document(s) under which the data and/or specimens were collected included for review? |
| [ ]  **YES** [ ]  **NO** | Were all data and/or specimens obtained solely for the purpose of research under a process of broad consent? (see Broad Consent Section below) |
| [ ]  **YES** [ ]  **NO** | Broad consent was documented for all data and specimens (without waiver or alteration)? |
| [ ]  **YES** [ ]  **NO** | The planned research is within the scope of the broad consent that was signed by participants? |
| [ ]  **YES** [ ]  **NO** | The plan in this proposed research does not include the individual return of results to study participants?  |
| **Broad Consent** | **Did the broad consent process meet the following elements:** [**45 CFR 46.116(a)(1)-(4)**](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/revised-common-rule-regulatory-text/index.html#46.116)**, and (a)(6)**  |
| [ ]  **YES** [ ]  **NO** | [ ]  Is the broad consent document accompanying this submission?[ ]  Before involving a human subject in research covered by this policy, an investigator shall obtain the legally effective informed consent of the subject or the subject's legally authorized representative[ ]  An investigator shall seek informed consent only under circumstances that provide the prospective subject or the legally authorized representative sufficient opportunity to discuss and consider whether to participate and that minimize the possibility of coercion or undue influence.[ ] The information that is given to the subject or the legally authorized representative shall be in language understandable to the subject or the legally authorized representative.[ ] The prospective subject or the legally authorized representative must be provided with the information that a reasonable person would want to have in order to make an informed decision about whether to participate, and an opportunity to discuss that information.[ ]  No informed consent may include any exculpatory language through which the subject or the legally authorized representative is made to waive or appear to waive any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the institution, or its agents from liability for negligence. |
|  | **Does the Broad Consent Document contain the following elements under** [**46.116(d)(1)-(7)**](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/revised-common-rule-regulatory-text/index.html#46.116)**:** |
| [ ]  **YES** [ ]  **NO** | [ ]  A description of any reasonably foreseeable risks or discomforts to the subject;[ ]  A description of any benefits to the subject or to others that may reasonably be expected from the research;[ ]  A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained;[ ]  A statement that participation is voluntary and that refusal to participate or a decision to terminate their participation will involve no penalty or loss of benefits to which the participant is otherwise entitled, and the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled; [ ]  A general description of the types of research that may be conducted with the identifiable private information or identifiable biospecimens. This description must include sufficient information such that a reasonable person would expect that the broad consent would permit the types of research conducted;[ ]  A description of the identifiable private information or identifiable biospecimens that might be used in research, whether sharing of identifiable private information or identifiable biospecimens might occur, and the types of institutions or researchers that might conduct research with the identifiable private information or identifiable biospecimens;[ ]  A description of the period of time that the identifiable private information or identifiable biospecimens may be stored and maintained (which period of time could be indefinite), and a description of the period of time that the identifiable private information or identifiable biospecimens may be used for research purposes (which period of time could be indefinite);[ ]  Unless the subject or legally authorized representative will be provided details about specific research studies, a statement that they will not be informed of the details of any specific research studies that might be conducted using the subject's identifiable private information or identifiable biospecimens, including the purposes of the research, and that they might have chosen not to consent to some of those specific research studies;[ ]  A statement regarding whether clinically relevant research results, including individual research results, will be disclosed to subjects, and if so, under what conditions; and[ ]  An explanation of whom to contact for answers to questions about the subject's rights and about storage and use of the subject's identifiable private information or identifiable biospecimens, and whom to contact in the event of a research-related harm. |
|  | **Are the following additional elements applicable and met:** |
| Based on the attestation are these additional elements included?[ ]  **YES** [ ]  **NO** | [ ]  A statement that the subject's biospecimens (even if identifiers are removed) may be used for commercial profit and whether the subject will or will not share in this commercial profit[ ]  For research involving biospecimens, whether the research will (if known) or might include whole genome sequencing (*i.e.,* sequencing of a human germline or somatic specimen with the intent to generate the genome or exome sequence of that specimen). |
| **Reviewer Recommendation or Approval**  |
| [ ]  **Expedited Review** | [ ]  **Convened Board Review** |
| [ ]  Approved[ ]  Refer to Convened Board[ ] Recommend Disapproval to Convened Board | [ ] Approved [ ]  Conditionally Approve[ ]  Defer [ ]  Disapproval |
| **MAJOR STIPULATIONS:**Click or tap here to enter text. |
| **MINOR STIPULATIONS:**Click or tap here to enter text. |
| **ADDITIONAL COMMENTS** (INCLUDING JUSTIFICATION FOR RECOMMENDATION FOR RESEARCH DISAPPROVAL)**:**Click or tap here to enter text. |
| Click or tap here to enter text.**Reviewer Name/Signature** | Click or tap to enter a date.**Date** |